Clinical trials
Locally Advanced (Unresectable) or Metastatic Solid Tumors clinical trials
Below are recruiting locally advanced (unresectable) or metastatic solid tumors clinical trials, each written for real people, not researchers. We’re tracking 2,077 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06771739Recruiting
Paying patients with early-stage cancer extra money
This trial is testing whether giving patients with early-stage cancer extra money to pay for non-medical needs helps them. If you are getting treatment at PeaceHealth and have some financial worries, you may be able to join.
Bellingham, WashingtonAges 18 years+ - NCT04341181RecruitingPhase 2
Targeted cancer treatment chosen by tumor genetic test results
This Phase 2 trial matches people with advanced cancer to a targeted treatment based on a genetic (DNA) or protein (IHC) test from their tumor. It’s for cancers that are no longer responding to standard treatment or where no standard option is available.
Aalborg, AalborgAges 18 years+ - NCT06764316RecruitingPhase 1
Safety study of BAY 3547926 for advanced liver cancer
This trial tests a new drug called BAY 3547926 for people with advanced liver cancer that cannot be removed with surgery or has not responded to other treatments. The goal is to see if the drug is safe and how well it works.
Dothan, AlabamaAges 18 years+ - NCT06765109RecruitingPhase 3
Testing neladalkib for untreated ALK-positive lung cancer
This study tests a new pill called neladalkib to see if it works better than the current standard treatment (alectinib) for people with ALK-positive lung cancer who have not yet received any cancer therapy for advanced disease. It may be a good option if you have ALK-positive NSCLC and have not been treated before.
Glendale, ArizonaAges 18 years+ - NCT06750484RecruitingPhase 2
Testing trastuzumab deruxtecan in HER2-zero breast cancer
This trial tests a new drug called trastuzumab deruxtecan (a targeted antibody-drug combination) for people with advanced breast cancer that never showed any HER2 protein (HER2-zero). The goal is to see if it can shrink tumors and improve outcomes for those who have already had standard treatments.
New Haven, ConnecticutAges 18 years+ - NCT06753747RecruitingPhase 1/Phase 2
Afatinib and palbociclib for advanced esophageal cancer
This trial tests a combination of two targeted drugs (afatinib and palbociclib) for people with advanced esophageal squamous cell carcinoma that has grown after previous treatment. It is designed for those whose cancer cells have too much of a protein called EGFR.
Chengdu, SichuanAges 18–75 - NCT04993131Recruiting
Liver transplant for non-surgical bile duct cancer
This trial studies liver transplantation for people with a specific type of bile duct cancer near the liver that cannot be safely removed by surgery. It aims to improve outcomes by offering a transplant after the cancer responds to chemotherapy and spread has been ruled out on scans.
OsloAges 18 years+ - NCT06741085RecruitingPhase 2
Radiosurgery plus standard care for lung cancer spread to brain
This trial tests if adding stereotactic radiosurgery (focused radiation) to standard drug therapy is safe and effective for people with EGFR-mutant non-small cell lung cancer that has spread to the brain. It aims to improve control of brain metastases while continuing targeted therapy.
Miami, FloridaAges 18 years+ - NCT06731478RecruitingPhase 3
New drug combo for first treatment of HER2-positive stomach cancer
This trial tests a new targeted drug (TDXd) combined with chemotherapy, pembrolizumab, and trastuzumab for people with HER2-positive stomach or gastroesophageal junction cancer that has spread or cannot be removed by surgery. It aims to see if this combination works better than standard treatments as a first therapy.
New Haven, ConnecticutAges 18 years+ - NCT06728410RecruitingPhase 2
Pemigatinib plus durvalumab for advanced bile duct cancer
This trial tests a combination of two drugs, pemigatinib and durvalumab, in people with a certain type of advanced bile duct cancer that has a specific genetic change (FGFR2 fusion or rearrangement). The goal is to see if this combination can help when standard treatments have stopped working.
Birmingham, AlabamaAges 18 years+ - NCT06709495RecruitingPhase 1/Phase 2
PEEL-224 with chemo for teens and young adults with sarcoma
This trial tests a new drug called PEEL-224 combined with two chemotherapy drugs (vincristine and temozolomide) for people ages 12 to 49 with sarcoma that has come back or hasn't responded to standard treatments. The goal is to see if this combination is safe and effective.
Boston, MassachusettsAges 12–49 - NCT06691425Recruiting
Radiation for pancreatic cancer that can't be removed
This trial tests a very focused type of radiation (SBRT) for people with pancreatic cancer that hasn't spread to other organs but can't be removed with surgery. It may be an option if you are medically unable to have surgery or choose not to.
Edegem, AntwerpenAges 18 years+ - NCT06695845RecruitingPhase 2
Study of zanidatamab for HER2-positive solid tumors
This trial tests a drug called zanidatamab in people with advanced solid tumors that have high levels of HER2 protein (called HER2-positive). It aims to see if zanidatamab can shrink or slow the growth of these tumors.
Prescott, ArizonaAges 18 years+ - NCT06703398RecruitingPhase 2
Study of GC101 TIL for advanced melanoma
This trial tests a new treatment called GC101 TIL for people with advanced melanoma that has not responded to other therapies. It involves taking immune cells from a tumor, growing them in a lab, and giving them back to fight the cancer.
BeijingAges 18–75 - NCT06678724Recruiting
Blood test study for head and neck cancer that has returned or spread
This trial is testing a new blood test (called a liquid biopsy) to better understand and predict the course of head and neck cancers that have come back or spread. If you join, researchers will use a special chip to look at your immune cells and tumor cells in your blood.
Zhubei, HsinChu CountyAges 20 years+ - NCT06663319RecruitingPhase 1
Study of JNJ-89402638 for metastatic colorectal and gastric cancers
This trial tests a new drug, JNJ-89402638, alone or with other treatments for people with metastatic colorectal or gastric cancer that has progressed after standard therapies. It aims to find safe and effective doses and combinations.
Tucson, ArizonaAges 18 years+ - NCT06648096RecruitingPhase 1/Phase 2
Testing afatinib for head and neck cancer in Fanconi anemia patients
This trial tests whether the targeted drug afatinib can shrink advanced head and neck cancers in people who also have Fanconi anemia. It is for patients whose tumors cannot be surgically removed and have not responded to or cannot have other standard treatments.
HanoverAges 18 years+ - NCT06632977RecruitingPhase 2
Matching targeted treatments to your prostate cancer's genetics
This trial is testing whether matching your cancer's specific genetic changes to a targeted treatment can help control metastatic prostate cancer that has stopped responding to standard hormone therapy and chemotherapy. You may receive a drug, a radioactive treatment, or a combination based on your tumor's molecular profile.
Birmingham, AlabamaAges 18 years+ - NCT06623461RecruitingPhase 2
Fecal transplant with immunotherapy for advanced melanoma
This trial tests if giving a special capsule of donated bacteria (fecal transplant) alongside standard immunotherapy helps shrink tumors in people with advanced melanoma. It aims to see if adding the bacteria can make the immune therapy work better.
Abbotsford British Columbia, British ColumbiaAges 18 years+ - NCT06623136RecruitingPhase 2
Testing a new combo for advanced lung cancer
This trial tests a new drug (ES102) combined with an immunotherapy (Toripalimab) for people with advanced non-small cell lung cancer that has stopped responding to standard treatments. It may help those whose tumors have high PD-L1 levels.
Beijing, Beijing MunicipalityAges 18–75 - NCT06622057RecruitingPhase 3
D07001 and capecitabine for advanced bile duct cancer
This trial tests a combination of two oral medications, D07001 and capecitabine, for people with advanced bile duct, gallbladder, or ampullary cancer that has gotten worse after standard chemotherapy. The goal is to see if this combination can help control the cancer.
Tucson, ArizonaAges 18 years+ - NCT06594991RecruitingPhase 2
A study of three immunotherapy drugs for advanced melanoma
This trial tests a combination of three immunotherapy drugs (fianlimab, cemiplimab, and ipilimumab) for people with advanced melanoma that has stopped responding to previous PD-1/PD-L1 treatment. It aims to see if this new combination can help shrink or control the cancer.
Los Angeles, CaliforniaAges 18 years+ - NCT06241846RecruitingPhase 2
Study of YL201 for advanced prostate cancer that has spread and stopped responding to hormone therapy
This trial tests a new drug, YL201, in men with advanced prostate cancer that has spread and is no longer controlled by standard hormone therapy. The goal is to see if YL201 can shrink tumors or slow the cancer's growth.
Hefei, AnhuiAges 18 years+ - NCT06562543RecruitingPhase 4
Fruquintinib for advanced colorectal cancer in minority populations
This trial tests a medication called fruquintinib (an oral pill) for people with advanced colorectal cancer that has not responded to prior treatments. It is specifically looking for participants who identify as Black or African American and/or Hispanic or Latino to help understand how the drug works in these groups.
Birmingham, AlabamaAges 18 years+
Hear when a new Locally Advanced (Unresectable) or Metastatic Solid Tumors trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for locally advanced (unresectable) or metastatic solid tumors?
- Yes. Clin2 currently lists 2,077 recruiting locally advanced (unresectable) or metastatic solid tumors studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a locally advanced (unresectable) or metastatic solid tumors trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a locally advanced (unresectable) or metastatic solid tumors trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
- Locally Advanced or Metastatic Solid Tumors
- Locally Advanced/Metastatic Solid Tumors
- Advanced or Metastatic Solid Tumors
- Advanced/Metastatic Solid Tumors
- Locally Advanced or Metastatic Breast Cancer
- Locally Advanced Solid Tumor
- Locally Advanced Malignant Solid Neoplasm
- Locally Advanced or Metastatic Non-small Cell Lung Cancer
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.